MAGE-A4 Peptide-MHC Binding Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TCR-based T cell therapies for cancers like non-small cell lung cancer, melanoma, bladder, and head and neck cancers face challenges due to low binding affinity for MAGE-A4 peptide-MHC targets and are laborious and costly to develop, while generating monoclonal antibodies against these targets is difficult due to the small epitope of the bound peptide in HLA.
Innovation Solution
Development of antigen binding proteins with specific characteristics, such as binding affinities ranging from 10^-9 M to 10^-14 M for MAGE-A4 peptide-MHC, and low affinity for non-target MAGE-A4 peptide-MHC or peptide-free MHC, utilizing specific amino acid sequences and antibody domains like scFv, Fab, or VHH to recognize MAGE-A4 peptide-MHC with high specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TCR-based T cell therapy is used to target MAGE-A4 peptide-MHC, then cancer treatment capability is provided, but binding affinity is low
Solution Approach 1:
The patent changes the binding parameters by developing antigen binding proteins with optimized variable domains (VH and VL) that achieve binding affinities of 10^-9 M to 10^-14 M for MAGE-A4 peptide-MHC, significantly improving upon the low affinity of conventional TCR-based approaches while maintaining therapeutic effectiveness
Solution Approach 2:
The invention creates composite antigen binding proteins that combine heavy chain variable domains (VH) and light chain variable domains (VL) with specific CDR regions designed to recognize MAGE-A4 peptide-MHC complexes, achieving both high affinity and high specificity through the composite structure of these domains
2Reliability
If monoclonal antibodies are generated against pMHC targets, then binding affinity is high, but generation process is difficult
Solution Approach 1:
The patent segments the antibody structure into separate heavy chain variable domain (VH) and light chain variable domain (VL) components, each with defined CDR regions. This segmentation allows for modular design and construction of antigen binding proteins with specific affinities, simplifying the generation process compared to traditional monoclonal antibody production
Solution Approach 2:
The invention systematically varies the CDR region sequences in the VH and VL domains to optimize binding affinity for MAGE-A4 peptide-MHC while maintaining manufacturability. This parameter optimization approach enables controlled generation of high-affinity binders without the complexity of traditional hybridoma technology
3Reliability
If antigen binding protein binds to MAGE-A4 peptide-MHC with high affinity, then specificity is improved, but off-target binding may occur
Solution Approach 1:
The patent optimizes the local quality of the CDR regions in the VH and VL domains to specifically recognize unique epitopes of the MAGE-A4 peptide-MHC complex. By fine-tuning the amino acid sequences in CDR1, CDR2, and CDR3 regions, the antigen binding proteins achieve high specificity for the target while minimizing off-target binding to non-MAGE-A4 pMHC or peptide-free MHC
Solution Approach 2:
The antigen binding proteins serve as intermediaries that specifically recognize and bind to the MAGE-A4 peptide-MHC complex through their optimized VH and VL domains. This specific recognition acts as a selective mediator that distinguishes target cells from non-target cells, reducing harmful off-target effects while maintaining high binding affinity for the intended target
Data Source
AI summary
Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.